Risk Factors for Perinatal Transmission of Hepatitis C Virus
Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: To estimate the rate of perinatal transmission of hepatitis C virus (HCV) infection, to identify risk factors for perinatal transmission of HCV infection, and to determine the viremic threshold for perinatal transmission.
METHODS: This was a prospective, multicenter, observational study of pregnant individuals at less than 24 weeks of gestation screened for HCV infection from 2012 to 2018 in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Individuals found to be HCV antibody-positive were followed throughout pregnancy. Children were followed for evidence of perinatal transmission at 2-6 months (HCV RNA testing) and at 18-24 months (HCV RNA and antibody testing) of life. The primary outcome was perinatal transmission, defined as positive test results at either follow-up time point.
RESULTS: A total of 109,379 individuals were screened for HCV infection. Of the 1,224 participants who screened positive, 772 (63.1%) enrolled and 432 of those 772 (56.0%) had data available to assess primary outcome. The overall rate of perinatal transmission was 6.0% (26/432, 95% CI 4.0-8.7%). All children with HCV infection were born to individuals with demonstrable viremia. In viremic participants (n=314), the perinatal transmission rate was 8.0% (95% CI 5.2-11.5%). Risk factors for perinatal transmission included HCV RNA greater than 106 international units/mL (adjusted odds ratio [aOR] 8.22, 95% CI 3.16-21.4) and vaginal bleeding reported at any time before delivery (aOR 3.26, 95% CI 1.32-8.03). A viremic threshold for perinatal transmission could not be established.
CONCLUSION: Perinatal transmission of HCV infection was limited to viremic individuals. High viral loads and antepartum bleeding were associated with perinatal transmission.
| Errataetall: |
CommentIn: Obstet Gynecol. 2023 Sep 1;142(3):447-448. - PMID 37535958 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
Obstetrics and gynecology - 142(2023), 3 vom: 01. Sept., Seite 449-456 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 05.03.2024 published: Print CommentIn: Obstet Gynecol. 2023 Sep 1;142(3):447-448. - PMID 37535958 Citation Status MEDLINE |
|---|
| doi: |
10.1097/AOG.0000000000005306 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360898882 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360898882 | ||
| 003 | DE-627 | ||
| 005 | 20240305231934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/AOG.0000000000005306 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM360898882 | ||
| 035 | |a (NLM)37590978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prasad, Mona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk Factors for Perinatal Transmission of Hepatitis C Virus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Obstet Gynecol. 2023 Sep 1;142(3):447-448. - PMID 37535958 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To estimate the rate of perinatal transmission of hepatitis C virus (HCV) infection, to identify risk factors for perinatal transmission of HCV infection, and to determine the viremic threshold for perinatal transmission | ||
| 520 | |a METHODS: This was a prospective, multicenter, observational study of pregnant individuals at less than 24 weeks of gestation screened for HCV infection from 2012 to 2018 in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Individuals found to be HCV antibody-positive were followed throughout pregnancy. Children were followed for evidence of perinatal transmission at 2-6 months (HCV RNA testing) and at 18-24 months (HCV RNA and antibody testing) of life. The primary outcome was perinatal transmission, defined as positive test results at either follow-up time point | ||
| 520 | |a RESULTS: A total of 109,379 individuals were screened for HCV infection. Of the 1,224 participants who screened positive, 772 (63.1%) enrolled and 432 of those 772 (56.0%) had data available to assess primary outcome. The overall rate of perinatal transmission was 6.0% (26/432, 95% CI 4.0-8.7%). All children with HCV infection were born to individuals with demonstrable viremia. In viremic participants (n=314), the perinatal transmission rate was 8.0% (95% CI 5.2-11.5%). Risk factors for perinatal transmission included HCV RNA greater than 106 international units/mL (adjusted odds ratio [aOR] 8.22, 95% CI 3.16-21.4) and vaginal bleeding reported at any time before delivery (aOR 3.26, 95% CI 1.32-8.03). A viremic threshold for perinatal transmission could not be established | ||
| 520 | |a CONCLUSION: Perinatal transmission of HCV infection was limited to viremic individuals. High viral loads and antepartum bleeding were associated with perinatal transmission | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a Saade, George R |e verfasserin |4 aut | |
| 700 | 1 | |a Clifton, Rebecca G |e verfasserin |4 aut | |
| 700 | 1 | |a Sandoval, Grecio J |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Brenna L |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Uma M |e verfasserin |4 aut | |
| 700 | 1 | |a Bartholomew, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Chien, Edward K |e verfasserin |4 aut | |
| 700 | 1 | |a Tita, Alan T N |e verfasserin |4 aut | |
| 700 | 1 | |a Thorp, John M |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Metz, Torri D |e verfasserin |4 aut | |
| 700 | 1 | |a Wapner, Ronald J |e verfasserin |4 aut | |
| 700 | 1 | |a Sabharwal, Vishakha |e verfasserin |4 aut | |
| 700 | 1 | |a Simhan, Hyagriv N |e verfasserin |4 aut | |
| 700 | 1 | |a Swamy, Geeta K |e verfasserin |4 aut | |
| 700 | 1 | |a Heyborne, Kent D |e verfasserin |4 aut | |
| 700 | 1 | |a Sibai, Baha M |e verfasserin |4 aut | |
| 700 | 1 | |a Grobman, William A |e verfasserin |4 aut | |
| 700 | 1 | |a El-Sayed, Yasser Y |e verfasserin |4 aut | |
| 700 | 1 | |a Casey, Brian M |e verfasserin |4 aut | |
| 700 | 1 | |a Parry, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rathore, Mobeen |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz-Velasco, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Puga, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Wiznia, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacs, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Garry, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Macones, George A |e verfasserin |4 aut | |
| 700 | 0 | |a Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network* |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology |d 1953 |g 142(2023), 3 vom: 01. Sept., Seite 449-456 |w (DE-627)NLM000021555 |x 1873-233X |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2023 |g number:3 |g day:01 |g month:09 |g pages:449-456 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/AOG.0000000000005306 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2023 |e 3 |b 01 |c 09 |h 449-456 | ||